AGENTURMELDUNGEN |
|---|
13:01 | 10.07.2009
PRESS RELEASE: HUGIN AD-HOC/MediGene AG: MediGene receives Positive Assessment on Market Authorisation for Veregen® in First European Countries
PRESS RELEASE: HUGIN AD-HOC/MediGene AG: MediGene receives Positive Assessment on Market Authorisation for Veregen® in First European Countries
MediGene AG / Misc. matters / Ad hoc: MediGene receives Positive
Assessment on Market Authorisation for
Veregen® in First European Countries
Ad hoc announcement according to §15 WpHG processed and transmitted
by Hugin. The issuer is solely responsible for the content of this
announcement.
=---------------------------------------------------------------------
=-------------
Martinsried/Munich, July 10, 2009. MediGene AG (Frankfurt: MDG, Prime
Standard, TecDAX) today announces that its Marketing Authorisation
Application for the medicinal product Veregen® (formerly Polyphenon
E® Ointment) for the treatment of genital warts has been assessed
positively by the national regulatory authorities of Germany,
Austria, and Spain. This binding decision guarantees that national
Marketing Authorisations in these countries will be formally granted
by the authorities within the next few months. The Marketing
Authorisation of Veregen® in Germany, the Reference Member State in
this Decentralized Procedure, shall provide the basis for additional
Marketing Authorisations in other European countries via the Mutual
Recognition Procedure.
This press release contains forward-looking statements representing
the opinion of MediGene as of the date of this release. The actual
results achieved by MediGene may differ significantly from the
statements made herein. MediGene is not bound to update any of these
forward-looking statements.
- ends -
Contact MediGene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
Germany
Email: investor@medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 -
85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
=-- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Regulierter Markt in Frankfurter Wertpapierbörse;
http://www.medigene.com
Copyright © Hugin AS 2009. All rights reserved.
(END) Dow Jones Newswires July 10, 2009 07:01 ET (11:01 GMT) |
| Weitere Meldungen |
|---|